A Study To Evaluate The Efficacy And Safety Of ALKS 2680 In Adults With Narcolepsy Type 1

Overview

About this study

The purpose of this study is to evaluate the efficacy of ALKS 2680 for the treatment of EDS in participants with NT1.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18 to 70 years

  • Participants with Narcolepsy Type 1

Exclusion Criteria:

  • Participants withoutNarcolepsy Type 1

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/26/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Chad Ruoff, M.D.

Contact us for the latest status

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available
.
CLS-20602720

Mayo Clinic Footer